model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT04279392,NCT04279392,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,"Healthy Body, Healthy Bones After Bariatric Surgery Trial",Zoledronic Acid to Prevent Bone Loss Following Sleeve Gastrectomy,True,0.9,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,"Feasibility of Bisphosphonate Use on Sleeve Gastrectomy Associated Bone Loss: Healthy Body, Healthy Bones Trial","Healthy Body, Healthy Bones: A Pilot Randomized Controlled Trial to Investigate the Use of Zoledronic Acid to Prevent Bone Loss 9 Months Following Sleeve Gastrectomy",True,0.92,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with bariatric surgery adversely affects bone leads to an increased risk of fracture. Bisphosphonate medications, such as zoledronic acid, are used to treat bone loss in patients with osteoporosis, and this study investigates whether this medication can prevent bone loss associated with surgical weight loss procedures.","Sleeve gastrectomy (SG) is an increasingly used and effective treatment for obesity; however, the rapid weight loss associated with SG adversely affects bone metabolism predisposing patients to skeletal fragility. Bisphosphonate medications have been evaluated for safety and efficacy in combating bone loss in patients with osteoporosis, but their use in SG-induced bone loss is limited. The goal of this study is to investigate how a one-time infusion of zoledronic acid compares to placebo, in its ability to combat SG-associated bone loss.",True,0.92,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,TP,TP,"One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with bariatric surgery adversely affects bone metabolism. Significant decreases in bone mineral density lead to an increased risk of fracture and subsequent reduction in physical function among bariatric surgery patients. Bisphosphonate medications, such as zoledronic acid, have been evaluated for safety and efficacy in combating bone loss in patients with osteoporosis, but their use in bariatric surgery-induced bone loss has not been explored. The primary goal of this study is to investigate whether bisphosphonate therapies are able to combat bone loss associated with surgical weight loss procedures. This research proposal is a 1-year, pilot randomized controlled trial (RCT) involving 30 adult sleeve gastrectomy patients randomized to receive either a one-time zoledronic acid infusion or placebo (n=15 per group). The investigators hypothesize that zoledronic acid, a standard treatment for low bone density, will be an effective intervention to reduce sleeve gastrectomy-induced bone loss. Bone loss is an unintended consequence of an otherwise life-saving procedure, with declining bone health potentially contributing to major morbidity in those undergoing a bariatric procedure. Identifying effective interventions to minimize bone loss is crucial for comprehensive treatment of patients who undergo bariatric surgery. Specific Aim 1: To determine the efficacy of zoledronic acid in preventing bone loss associated with sleeve gastrectomy (SG). Bone mineral density (BMD) and bone turnover markers will be measured at baseline and 9 months. The primary outcome is change in BMD as measured by Dual-energy x-ray absorptiometry (DXA). Secondary outcomes are change in BMD as measured by Quantitative Computed Tomography (QCT) and change in the serum bone turnover markers, urinary collagen type 1 cross-linked N-telopeptide (CTX; bone formation marker), serum type 1 procollagen N-terminal (P1NP; bone resorption marker), sclerostin, and osteocalcin. Specific Aim 2: To evaluate the feasibility of this trial in those who have undergone SG surgery. The feasibility will be assessed by documenting adverse events and compliance rates of the intervention at each study time point.","This research protocol is a 9-month, pilot randomized controlled trial (RCT) involving 30 adult SG patients randomised to receive an infusion of either 5 mg of zoledronic acid or placebo, 6 weeks following surgery. To be included participants must be <350 lbs/158.8 kg, free of bone-impacting pathologies or medications, and must have adequate serum calcium and vitamin D levels at baseline. The primary outcome is change in areal bone mineral density (aBMD) at the total hip. Secondary outcomes include change in aBMD of the femoral neck, and lumbar spine, and change in volumetric BMD at the lumbar spine. The primary aim will be tested using a linear mixed model fit with total hip aBMD at 9 months as the outcome. Treatment, participant sex and menopausal status will be considered in analysis. Groups will be compared using contrast statements at 9 months, with change over 9 months being the primary comparison.

This pilot quadruple-blinded (participant, care provider, investigator and outcomes assessor are blinded to the treatment group) RCT anticipates 30 participants (15 per group) assigned (via computer-generated 1:1 block randomisation, with stratification by sex) to receive a one-time 100 mL infusion of 5 mg zoledronic acid or saline 6–8 weeks following SG. Study assessments will occur at baseline (prior to surgery) and at 9 months postoperatively.

The study includes comprehensive bone health measures including DXA scans (total body, hip, femoral neck, lumbar spine), QCT of the lumbar spine, bone turnover markers (P1NP and NTX), physical function testing (5 times sit to stand, hand grip strength, 4-metre walk test), and self-report surveys (HAP, KOOS, NOF calcium intake). All participants will receive calcium (1200 mg daily) and vitamin D supplementation (1000-2000 IU daily based on baseline levels) throughout the study duration. The infusion visit will take place 6-8 weeks following surgery after confirming adequate kidney function (eGFR ≥35 mL/min).",True,0.86,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,"['Bariatric Surgery Candidate', 'Bone Loss', 'Bone Resorption']","['Obesity', 'Bone Loss', 'Osteoporosis', 'Sleeve Gastrectomy']",False,0.3333333333333333,partial,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Sleeve Gastrectomy', 'Bariatric Surgery', 'Bone Mineral Density', 'Zoledronic Acid', 'Bisphosphonates', 'Bone Loss', 'Osteoporosis', 'Weight Loss Surgery', 'Bone Health', 'Bone Turnover Markers', 'DXA', 'Quantitative CT', 'Physical Function']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,FP,"['PHASE1', 'PHASE2']",['NA'],False,0.0,disjoint,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,QUADRUPLE,QUADRUPLE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,TP,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']","['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']",True,1.0,exact,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,FP,10,30,False,0.2,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].type,EV,EV,,DIETARY_SUPPLEMENT,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,DIETARY_SUPPLEMENT,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].type,EV,EV,,DIETARY_SUPPLEMENT,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].name,EV,EV,,Calcium,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,Vitamin D,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].name,EV,EV,,ProCare Bariatric Vitamins,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].description,EV,EV,,1200 mg of calcium daily provided to all participants throughout the study duration (from baseline through 9 months post-surgery) as per ASMBS guidelines.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,"Vitamin D supplementation provided to all participants throughout the study duration. Dosing is based on baseline 25(OH)D blood levels: 1000 IU daily for participants with serum D levels ≥30 ng/mL, and 2000 IU daily for participants with levels of 20-29 ng/mL.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].description,EV,EV,,ProCare Bariatric vitamins provided to all participants throughout the study duration as per ASMBS guidelines.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].armGroupLabels,EV,EV,,"['Zoledronic Acid', 'Placebo']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,"['Zoledronic Acid', 'Placebo']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].armGroupLabels,EV,EV,,"['Zoledronic Acid', 'Placebo']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].measure,EV,EV,,Feasibility: Adverse events and side effects,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].measure,EV,EV,,Feasibility: Compliance rates,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].measure,EV,EV,,Change in serum bone formation marker (P1NP),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].measure,EV,EV,,Change in bone resorption marker (NTX),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].measure,EV,EV,,Change in lower extremity strength and function,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].measure,EV,EV,,Change in functional mobility,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].description,EV,EV,,Documentation of adverse events and side effects at each study time point to assess safety and feasibility of zoledronic acid infusion in sleeve gastrectomy patients,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].description,EV,EV,,Documentation of compliance rates at each study time point to assess feasibility of the trial protocol in sleeve gastrectomy patients,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].description,EV,EV,,Change in serum type 1 procollagen N-terminal propeptide (P1NP) measured by ELISA from baseline to 9 months following sleeve gastrectomy,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].description,EV,EV,,Change in urinary collagen type 1 cross-linked N-telopeptide (NTX) measured by ELISA from baseline to 9 months following sleeve gastrectomy,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].description,EV,EV,,Change in 5 Times Sit to Stand test performance from baseline to 9 months following sleeve gastrectomy,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].description,EV,EV,,Change in 4-metre walk test performance from baseline to 9 months following sleeve gastrectomy,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].timeFrame,EV,EV,,"Throughout the 9-month study period (infusion visit, 24 hours post-infusion, 2 months post-infusion, and 9-month follow-up)",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].timeFrame,EV,EV,,Throughout the 9-month study period,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame,EV,EV,,Baseline (prior to surgery) and 9 months postoperatively,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame,EV,EV,,Baseline (prior to surgery) and 9 months postoperatively,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].timeFrame,EV,EV,,Baseline (prior to surgery) and 9 months postoperatively,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].timeFrame,EV,EV,,Baseline (prior to surgery) and 9 months postoperatively,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Subjects planning a sleeve gastrectomy procedure at the University of Nebraska Medical Center (UNMC) Bariatric Center
* Agreement to all study procedures and assessments
* Women must be postmenopausal (FSH blood level \> 30 mIU/m), or incapable of child-bearing

Exclusion Criteria:

* Prior bariatric surgery
* \< 19 years of age
* Weight ≥ 350lbs
* Liver or renal disease
* Hypercalcemia, hypocalcemia, or hypomagnesemia
* Serum 25-OH vitamin D \< 20 ng/mL
* History of bone-modifying disorders
* Use of bone-active medications
* Known sensitivity to bisphosphonates
* Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 6 months
* Current diagnosis of type 1 diabetes
* Current malignancy
* Autoimmune disease impacting bone (ex: Rheumatoid Arthritis)","Inclusion Criteria:
- Subjects planning a sleeve gastrectomy procedure at the study bariatric surgery centre.
- Agreement to all study procedures and assessments.
- Women must be postmenopausal (Follicle-stimulating hormone blood level >30 mIU/m), or incapable of childbearing (non-hormonal long-term birth control*).
- ≥19 years of age.
- Weight <350 lbs/158.8 kg.

Exclusion Criteria:
- Prior bariatric surgery.
- <19 years of age.
- Weight ≥350 lbs.
- Liver or renal disease.
- Hypercalcaemia, hypocalcaemia or hypomagnesaemia.
- Serum 25-OH vitamin D <20 ng/mL.
- History of bone-modifying disorders.
- Use of bone-active medications.
- Known sensitivity to bisphosphonates.
- Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 6 months.
- Current diagnosis of type 1 diabetes.
- Current malignancy.
- Autoimmune disease impacting bone (eg, rheumatoid arthritis).

*Given the risks of zoledronic acid on fetal development, there are risks to including women of childbearing capacity. However, premenopausal women with documented non-hormonal intrauterine devices in the study population will mitigate this risk. Although there is consensus that pregnancy should be avoided for 12–24 months following bariatric surgery, many women in this population regain fertility and become pregnant following surgery. Research has shown that hormonal contraceptives may not be as efficacious in women with obesity, and bariatric surgery has been shown to impact absorption and efficacy of oral contraception methods. For safety purposes, only premenopausal women with documented intrauterine devices will be eligible for this research study.",True,0.96,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,FP,True,False,False,0.0,success,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,19 Years,19 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
